Longeveron raises funds following more positive Alzheimer’s trial data

Company announces registered direct offering after revealing new data from Phase 2a trial of Lomecel-B in mild Alzheimer’s disease.
Shortly after releasing additional positive data from its Phase 2a Alzheimer’s trial, longevity biotech Longeveron (NASDAQ: LGVN) has annou…Read More

Longevity 2023: From A to…

An initial look at some of this year’s longevity news – literally. Including acid, the Amish, Amazon and Aging Hallmarks.
The longevity sector is booming with new companies exiting stealth, new products hitting the market and new research pushing the limits of both lifespan and healthspan, and we’ve published over 55…Read More

Interviews of 2023: the longevity companies

Six of our favourite interviews with companies operating at the cutting edge of longevity science.
From cellular reprogramming and SIRT6 to young blood and telomere boosting therapies, there are many different approaches being pursued by longevity companies. And we’ve spoken to them all. Here are s…Read More

Longevity 2023: …to X, Y, Z

Our second look at some of 2023’s longevity news, but this time from the other end of the alphabet, including XPRIZE, young blood and Zero.
Earlier in the week, we took a spin through a selection of longevity stories that had the letter A in common; as the year draws to a close, it’s time to flip to the other end o…Read More

Therapeutic plasma exchange – a new therapeutic modality for longevity

Healthy Longevity Clinic’s Dr Alison Levitt on why spring cleaning your blood could be the best thing for longevity.
Therapeutic plasma exchange (TPE), also known as plasmapheresis, has been used to treat diseases such as Guillain-Barré syndrome and multiple sclerosis, but…Read More

Moonwalk steps out with $57m for epigenetic reprogramming platform

Biotech co-founded by Alex Aravanis and Feng Zhang targets epigenetic code to reprogram cells to a healthy state.
Genomic medicine company Moonwalk Biosciences has emerged from stealth with $57 million in a combined seed and Series A financing to advance the development of…Read More

Vasa Therapeutics secures seed funding to target cardiovascular aging
Biopharma startup sets its sights on age related diseases, including heart failure, peripheral artery disease and sarcopenia.
US-Polish biopharma Vasa Therapeutics has closed a seed funding round, securing $6 million to advance the development of therapies focused on…Read More

How resetting the rhythm might help beat Alzheimer’s

Kate Turley on how realigning circadian rhythms could improve sleep and contribute to the slowing of the progression of dementia.
The circadian rhythm governs many daily functions of living organisms, including sleep-wake cycles, mood, rest-activity patterns, metabolism and hormone b…Read More

Bolden bags new funding to advance neurogenesis-boosting therapeutics

LifeSpan Vision Ventures backs Boston biotech working on treatments that generate new brain cells from existing neural stem cells.
Biotechnology firm Bolden Therapeutics revealed it has secured an undisclosed amount of funding from LifeSpan Vision Ventures to advance…Read More

Gallant raises $15m to advance stem cell therapies for pets

Pet longevity biotech is developing ready-to-use doses of allogeneic stem cell therapeutics targeting chronic diseases in dogs and cats.
Animal health biotech Gallant Therapeutics has secured more than $15 million in Series A financing to advance its “off-the-shelf” stem cell the…Read More